BioAge Labs, Inc (BIOA)vsTeva Pharma Industries Ltd ADR (TEVA)
BIOA
BioAge Labs, Inc
$15.70
-7.76%
HEALTHCARE · Cap: $713.02M
TEVA
Teva Pharma Industries Ltd ADR
$34.43
-2.76%
HEALTHCARE · Cap: $40.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 168076% more annual revenue ($17.35B vs $10.32M). TEVA leads profitability with a 9.0% profit margin vs 0.0%. TEVA earns a higher WallStSmart Score of 66/100 (B-).
BIOA
Hold35
out of 100
Grade: F
TEVA
Strong Buy66
out of 100
Grade: B-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 91.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BIOA
The strongest argument for BIOA centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 91.0% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.
Bear Case : BIOA
The primary concerns for BIOA are EPS Growth, Market Cap, Profit Margin.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
BIOA profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.
BIOA is growing revenue faster at 91.0% — sustainability is the question.
BIOA generates stronger free cash flow (-24M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TEVA scores higher overall (66/100 vs 35/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioAge Labs, Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various customers in the chemical market primarily in the United States and Canada. The company is headquartered in Montreal, Canada.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?